Skip to main navigation
  • Find a Doctor »
open
x
  • Neuronetics
    • Solutions
    • Investors
      • Overview
      • Stock Information
      • News & Events
      • Financial Information
      • Corporate Governance
      • Investor Resources
    • Meet the Team
    • News
    • Careers
  • For Patients
  • For Physicians
  • For Patients
  • For Physicians
  • Neuronetics
  • Why NeuroStar
  • About NeuroStar
  • Patient Corner
  • Insurance
  • About NeuroStar
  • Technology
  • Practice Support
  • Insurance
  • Solutions
  • Investors
  • Meet the Team
  • News
  • Careers
  • Contact Us
  • Global Sites
    • English
    • Deutsch
    • 日本語
    • 한국어
  • How it Works
  • Safety & Tolerability
  • Is it Right for You?
  • Clinical Results
  • Proven Efficacy
  • Safety
  • Mechanism of Action
  • The Key Role
  • Qualified Candidates
  • Scientific Publications
  • Unique Coil
  • TrakStar
  • MT Assist
  • Contact Sensing Advantage
  • Practice Setting
  • Physician Experiences
  • Success Program
  • Clinical Training
  • Field Service
  • Patient Education
  • Public Relations
  • Providers
  • Events and Exhibits
  • Coding and Billing
  • Medical Coverage Policies
  • Health Insurance Coverage
  • Services
  • Resources
  • Overview
  • Stock Information
  • News & Events
  • Financial Information
  • Corporate Governance
  • Investor Resources
  • Neuronetics Board
  • Precision
  • Facts vs Myths
  • About Depression

Presentations

Presentations

Events and Presentations

  • Press Coverage
  • News Releases
  • Investor Calendar
  • Presentations
Webcast
ICR Westwicke Conference 2021 – Panel: Non-Drug Therapeutics: Devices Changing the Treatment Paradigm
01/14/21 at 1:45 PM EST
Date Title
11/02/20
Neuronetics, Inc. Supplemental Financial and Operating Information
11/02/20
STIM Corporate Presentation November 2020
Printer Friendly Version View printer-friendly version
RSS RSS Feeds
E-mail Alerts E-mail Alerts
View contacts View contacts

Indication
NeuroStar TMS Therapy is indicated for the treatment of Major Depressive Disorder in adult patients who have failed to receive satisfactory improvement from prior antidepressant medication in the current episode.

NeuroStar TMS Therapy is only available by prescription. A doctor can help decide if NeuroStar TMS Therapy is right for you.


Important Safety Information
The most common side effect is pain or discomfort at or near the treatment site. These events are transient; they occur during the TMS treatment course and do not occur for most patients after the first week of treatment. There is a rare risk of seizure associated with the use of NeuroStar TMS (<0.1% per patient).

NeuroStar TMS Therapy should not be used with patients who have non-removable conductive metal in or near the head. NeuroStar TMS Therapy has not been studied in patients who have not received prior antidepressant treatment.
Safety and Prescribing Information »

Our Commitment
Neuronetics is committed to compliance with state and federal laws regarding interaction with healthcare providers.
Commitment to Compliance »


  • Neuronetics Resources
    • Solutions
    • Investors
    • Team
    • Careers
    • Find a Doctor
  • About NeuroStar
    • Patients
    • Healthcare providers
    • Contact Us
    • In the News
    • Prescribing Information
  • International
    • English
    • Deutsch
    • 日本語
    • 한국어
  • Website
    • Sitemap
    • Glossary
    • References
    • Privacy Policy
    • Terms & Conditions
  • Contact Us
    • 1-877-600-7555
    • Facebook
    • Twitter
    • Instagram
    • YouTube
    • LinkedIn

Copyright @ 2021 Neuronetics. All Rights Reserved.